Catalyst Biosciences Announces Proposed Public Offering of Common Stock
12 févr. 2020 16h15 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and...
Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Congress
07 févr. 2020 03h30 HE
|
Catalyst Biosciences, Inc.
Enrollment in the DalcA trial is complete; results demonstrate DalcA provides Factor IX (FIX) activity exceeding the efficacy endpoint with no anti-drug antibodies Company to host investor call and...
Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress
27 janv. 2020 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of the...
Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors
17 janv. 2020 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and...
Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
19 déc. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO), today announced it has entered into a global license and collaboration agreement with Biogen...
Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference
09 déc. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and...
Catalyst Biosciences to Present at the Stifel Healthcare Conference
12 nov. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update
07 nov. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30,...
Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference
06 nov. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel medicines to address hematology...
Catalyst Biosciences Provides DalcA Phase 2b Trial Update
03 oct. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a...